Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children
详细信息 查看全文
- 作者：Zhaoyang Peng ; Jianhua Mao ; Xuejun Chen ; Fengqing Cai ; Weizhong Gu…
- 关键词：suPAR ; Steroid resistance ; Primary nephrotic syndrome
- 刊名：Pediatric Nephrology
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：30
- 期：2
- 页码：301-307
- 全文大小：1,244 KB
- 参考文献：1. Thun? M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27:157-72 CrossRef
2. D’Alessio S, Blasi F (2009) The urokinase receptor as an entertainer of signal transduction. Front Biosci 14:4575-587 CrossRef
3. Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11:23-6 CrossRef
4. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P (2007) Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17:428-37 CrossRef
5. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55-3 CrossRef
6. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952-60 CrossRef
7. Kumagai T, Mouawad F, Takano T (2012) Pathogenesis of common glomerular diseases—role of the podocyte cytoskeleton. Cell Health Cytoskelet 2012:103-18
8. Zhang B, Xie S, Shi W, Yang Y (2012) Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27:1746-755 CrossRef
9. Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, Reiser J, Yang Y, Liu S, Wang W (2012) The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med 90:1407-420 CrossRef
10. Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 22:554-61 CrossRef
11. Sever S, Trachtman H, Wei C, Reiser J (2013) Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol 8:1273-275 CrossRef
12. Naesens M, Meijers B, Sprangers B (2013) suPAR and FSGS: the gap between bench and bedside. Transplantation 96:368-69 CrossRef
13. Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL (2013) Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29:144-49 CrossRef
14. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-876
15. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337-42 CrossRef
16. Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute / Plasmodium falciparum malaria infection. Parasite Immunol 26:207-11- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Pediatrics- 出版者：Springer Berlin / Heidelberg
- ISSN：1432-198X
文摘
Background Soluble urokinase plasminogen activator receptor (suPAR) has been regarded as a permeability factor in proteinuria, though its role in primary nephrotic syndrome remains to be elucidated further. Methods Plasma samples and clinical information from 176 children with primary nephrotic syndrome were collected and concentrations of suPAR were measured. We evaluated the correlation between suPAR concentrations and clinical features, and the value of the plasma suPAR level in predicting steroid-resistant nephrotic syndrome (SRNS). Results There is a significant difference in plasma suPAR concentration between SRNS and steroid-sensitive nephrotic syndrome (SSNS) groups (3,744.1?±-,226.0 vs. 2,153.5?±-,167.0, p--.05). The area under the curve (AUC) was 0.80, with p--.001 for the receiver operating characteristic (ROC) curve analysis using suPAR to predict SRNS. The suspicious range for predicting SRNS was estimated to be 1,907.0?pg/ml to 3,043.5?pg/ml (χ2--4.775, p--.001). Conclusions From ROC curve analysis, we demonstrated the significance of the suPAR level in predicting SRNS with a high specificity but low sensitivity. However, the clinical value of suPAR to predict steroid resistance and guide therapy remains to be investigated further.